The suggestion that longer 24-week dosing might improve Sofo/Riba GT3 SVR rates is non-sense. The difference between interferon-based and oral therapy is becoming quite clear. Whereas 24-weeks of interferon-based dosing brought exceedingly higher SVR rates this is not the case going beyond 12-weeks of oral treatment.
This is nothing more than false hope being fed to analysts.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.